My first DEXA scan on 05/08/07 diagnosed me with osteoporosis. My second scan was done 07/06/09 after the following treatment: Fosamax 70 mg weekly from 06/18/07 to 12/24/07, two capsules Doctor's Best Strontium Bone Maker daily from 01/21/08 to 07/06/09. Here are my BMD results in g/cm2 and my T-scores for my second scan:
Spine (L1-L4): BMD 0.749, T-Score -2.7
Lt. Hip (neck): BMD 0.563, T-Score -2.6
Lt. Hip (total): BMD 0.739, T-Score -1.7
Despite my best efforts, my scores were not corrected for strontium intake by the radiologist. My first and second scans were not on the same DEXA machine. Even so, I am very happy with my results. My T-scores improved 10.0% at the spine, 7.1% at the left hip (neck), and 22.7% at the left hip (total). I plan to continue taking strontium citrate.
WELCOME TO STRONTIUM FOR BONES BLOG
Have you experienced or read about negative, and even dangerous, side effects from Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), and other bisphosphonates prescribed for osteoporosis? If you have, then rest assured there is a safe, effective treatment for this condition. Strontium, primarily in the form of strontium citrate, is taken orally once a day. Studies have shown the bones it rebuilds may be stronger than those rebuilt by the bisphosphonates.
My blog offers visitors useful posts, which you may reply to, information concerning the use of strontium for osteoporosis, and an extensive link library of references. Your participation in occasional polls is welcome.
All comments to my posts are moderated by me.
My blog offers visitors useful posts, which you may reply to, information concerning the use of strontium for osteoporosis, and an extensive link library of references. Your participation in occasional polls is welcome.
All comments to my posts are moderated by me.
Saturday, July 11, 2009
Monday, June 22, 2009
Study Shows Protelos Builds Better Bone Than Fosamax
A two-year double-blind study included 88 women over age 50 with postmenopausal osteoporosis who were treated with either Protelos (strontium ranelate) 2 g. daily or Fosamax (alendronate) 70 mg. weekly. The study, which used high-resolution computerized tomography, showed that Protelos increased cortical bone thickness, bone volume and trabecular bone density to a significantly greater extent than Fosamax over a one-year period.
The one-year interim results on bone microstucture, a determinant of bone strength, showed a +5.3% increase in cortical thickness and a +2.0% increase in bone volume in the Protelos-treated group. There was no change in the Fosamax-treated group.
For more information and references, see www.medicalnewstoday.com/printerfriendlynews.php?newsid=132149
The one-year interim results on bone microstucture, a determinant of bone strength, showed a +5.3% increase in cortical thickness and a +2.0% increase in bone volume in the Protelos-treated group. There was no change in the Fosamax-treated group.
For more information and references, see www.medicalnewstoday.com/printerfriendlynews.php?newsid=132149
Thursday, May 28, 2009
Update On Strontium Malonate For Osteoporosis
Osteologix, Inc. has received a key U.S. Patent Allowance for its osteoporosis drug, NB S101 (strontium malonate). This brings the company closer to its goal of manufacturing and marketing a prescription strontium drug in the U.S.
The Notice of Allowance from the U.S. Patent and Trademark Office is for U.S. Patent Application Number 11/269,289 titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions." It allows claims covering the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate). The patent will most likely issue in the second half of 2009 and expire in 2024.
The company has a number of other pending patent applications covering various aspects of the NB S101 drug program, including composition, manufacturing and method of use patent applications. "Based on the Notice of Allowance and the claims allowed by the USPTO, we believe the intellectual property protections established by this US patent allowance, coupled with our recently upheld European equivalent, will significantly enhance our ability to finalize strong development collaborations with potential partners to complete the Phase III development of NB S101 in osteoporosis," stated Philip J. Young, President and Chief Executive Officer of Osteologix. This is from the company's website at http://www.osteologix.com/.
The Notice of Allowance from the U.S. Patent and Trademark Office is for U.S. Patent Application Number 11/269,289 titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions." It allows claims covering the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate). The patent will most likely issue in the second half of 2009 and expire in 2024.
The company has a number of other pending patent applications covering various aspects of the NB S101 drug program, including composition, manufacturing and method of use patent applications. "Based on the Notice of Allowance and the claims allowed by the USPTO, we believe the intellectual property protections established by this US patent allowance, coupled with our recently upheld European equivalent, will significantly enhance our ability to finalize strong development collaborations with potential partners to complete the Phase III development of NB S101 in osteoporosis," stated Philip J. Young, President and Chief Executive Officer of Osteologix. This is from the company's website at http://www.osteologix.com/.
Update on Strontium Citrate Clinical Trial
BoneLady's Question, May 18, 2009:
What is the latest news on the strontium citrate for osteoporosis clinical trial? I went to the UCD site and found no update since February. I also visited www.clinicaltrials.gov/ and did not find this study listed. Is the medical center still recruiting? If so, what is the projected start date for the trial?
SCOPE Study Coordinator's Reply, May 27, 2009:
At this time, we are recruiting and enrolling participants and will most likely be doing so through the end of the year. No results will be available until at least this time next year.
What is the latest news on the strontium citrate for osteoporosis clinical trial? I went to the UCD site and found no update since February. I also visited www.clinicaltrials.gov/ and did not find this study listed. Is the medical center still recruiting? If so, what is the projected start date for the trial?
SCOPE Study Coordinator's Reply, May 27, 2009:
At this time, we are recruiting and enrolling participants and will most likely be doing so through the end of the year. No results will be available until at least this time next year.
Monday, May 11, 2009
Strontium and Antibiotics
Strontium may reduce the absorption of tetracycline antibiotics (e.g., tetracycline, minocycline, doxycycline) and quinolone antibiotics (e.g., ciprofloxacin, norfloxacin, nalidixic acid) from the gut and could make them less effective.
If you are prescribed a course of one of these types of antibiotics you should stop taking strontium during the course of antibiotics.This information is from www.netdoctor.co.uk/medicines/100000762.html
If you are prescribed a course of one of these types of antibiotics you should stop taking strontium during the course of antibiotics.This information is from www.netdoctor.co.uk/medicines/100000762.html
Labels:
antibiotics,
osteoporosis,
quinolone,
strontium,
tetracycline
Monday, May 4, 2009
Poll Results On T-Scores After Strontium Citrate
Here are the results of my latest poll: Did your DEXA scan T-scores improve after taking strontium citrate?
12 (75%) YES
4 (25%) NO
12 (75%) YES
4 (25%) NO
Labels:
DEXA scan,
Strontium citrate,
T-scores
Subscribe to:
Posts (Atom)
How Strontium Builds Bones
Strontium is a mineral that tends to accumulate in bone. Studies have shown that oral doses of strontium are a safe and effective way to prevent and reverse osteoporosis. Doses of 680 mg per day appear to be optimal. See my "For More Information About Strontium" links section.
Osteoporosis is caused by changes in bone production. In healthy young bones there is a constant cycle of new bone growth and bone removal. With age, more bone is removed and less new bone is produced. The bones become less dense and thus more fragile.
Scientists believe that strontium works in two ways. It may stimulate the replication of pre-osteoblasts, leading to an increase in osteoblasts (cells that build bone). Strontium also directly inhibits the activity of osteoclasts (cells that break down bone). The result is stronger bones.
When taking strontium, be sure to take 1200 mg calcium, 1000 IU vitamin D3, and 500 mg magnesium daily. It is best to take strontium late at night on an empty stomach. Calcium and strontium may compete with each other for absorption if taken together.
Osteoporosis is caused by changes in bone production. In healthy young bones there is a constant cycle of new bone growth and bone removal. With age, more bone is removed and less new bone is produced. The bones become less dense and thus more fragile.
Scientists believe that strontium works in two ways. It may stimulate the replication of pre-osteoblasts, leading to an increase in osteoblasts (cells that build bone). Strontium also directly inhibits the activity of osteoclasts (cells that break down bone). The result is stronger bones.
When taking strontium, be sure to take 1200 mg calcium, 1000 IU vitamin D3, and 500 mg magnesium daily. It is best to take strontium late at night on an empty stomach. Calcium and strontium may compete with each other for absorption if taken together.
For More Information About Strontium
- Additional Positive Phase II Data for Strontium Malonate
- Correction Of BMD For Strontium
- National Osteoporosis Foundation
- Osteoporosis Info: Mayo Clinic
- PREVOS And STRATOS Clinical Trials Of Strontium For Treating Osteoporosis
- Servier Clinical Trial: Strontium For The Treatment Of Peripheral Osteoporosis
- Servier Clinical Trial: Strontium For The Treatment Of Vertebral Fractures
- Strontium and Osteoporosis
- Strontium Citrate Osteoblast Study
- Strontium Dexa Scan Effect
- Strontium Malonate for Osteoporosis Accepted by US FDA
- Strontium Malonate Phase II Trial Meets Primary Endpoint
- Strontium: Breakthrough Against Osteoporosis